Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis (PEKASYS)
Liver Cirrhosis, Portal Hypertension
About this trial
This is an interventional treatment trial for Liver Cirrhosis focused on measuring betablocker, aldosterone antagonist, peripheral haemodynamics, cardiac haemodynamics, oxygenation
Eligibility Criteria
Inclusion Criteria: Liver cirrhosis Clinical indication for treatment with betablocker or aldosterone antagonist Must not have been treated earlier with betablocker or aldosterone antagonist Must have been alcohol abstinent for more than 4 weeks Exclusion Criteria: Gastrointestinal bleeding in the last 2 weeks Encephalopathy > grade 1 Acute medical conditions Malignant disease Pregnancy
Sites / Locations
- Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
No Intervention
beta
spiron
control
patients with liver cirrhosis, treated with betablocker
patients with liver cirrhosis, treated with aldosterone antagonist
patients with liver cirrhosis, no treatment